HypErthermia as an Additional Treatment for the Biology and Experience of Depression
| 대상 질환 | Major Depressive Disorder |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | University of California, San Francisco |
| 상태 | 완료 |
| 참여자 수 | 16 명 |
| 중재(약물) | Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH) |
| 시작일 | 2021년 10월 11일 |
| 완료일 | 2023년 3월 1일 |
| 결과 공개일 | 2024년 6월 12일 |
요약
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or older with major depressive disorder (MDD).
Average Number of Planned WBH Sessions Completed
| Cognitive Behavioral Therapy (CBT) and 8 Sessions Whole-Body Hyperthermia (WBH) | 7.83 ± 0.41 Count of WBH Sessions |
|---|---|
| Cognitive Behavioral Therapy (CBT) and 4 Sessions Whole-Body Hyperthermia (WBH) | 3.20 ± 1.40 Count of WBH Sessions |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital